Overview

Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)

Status:
Terminated

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of Azimilide on the incidence of cardiovascular hospitalizations, cardiovascular emergency department visits or cardiovascular death in patients with Implantable Cardioverter Defibrillators (ICDs)

Phase:

Phase 3

Details

Lead Sponsor:

Forest Laboratories

Treatments:

Azimilide